Healthcare technology firm Lifespot Health has changed its name to InhaleRx in a move to better reflect the focus of the business.

The listed company will carry the ASX code IRX from today, switching from LSH which it adopted when it first went public in January 2017.

The new name will more accurately articulate its ambitions to commercialise vaping devices, with Rx a common shorthand for prescription, the firm said.

Lifespot entered the medicinal cannabis sector in May 2017 having initially listed on the ASX as a company specialising in the diagnosis and evaluation of skin disease.

InhaleRx chief executive Matthew Golden

“Inhale is the natural evolution of Lifespot Health,” the company said in a statement. “The board and management recognised that the strategic direction and future focus of Lifespot Health had changed significantly to the point that the name no longer reflected the company’s goals, aspirations and strategic direction.”

Chief executive Matthew Golden added: “When you look at where we are now and where we are heading, Lifespot Health didn’t really make a lot of sense.”

The business has also launched a new website at

Inhale recorded the first sales of its medicinal cannabis inhaler, Medihale, to Australian patients in May under the Special Access Scheme.

The sealed pod inhaler contains CBD e-liquid supplied by Melbourne-based pharmaceutical firm EC Pharma, which specialises in creating vaporised cannabinoids.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment